FDA Grants Fast Track Designation for Bexmarilimab
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Inside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS Company announcement, Inside Information, 26 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST Key highlights - Given the strong data seen in Phase 1 and continuing in Phase 2 of Faron’s BEXMAB trial, the FDA has granted Fast Track Designation (FTD) for bexmarilimab for the treatment of r/r MDS - FTD further strengthens the bexmarilimab program by offering clinical development and commercialization